Tessera Defense & Homeland Security Inc. (HLSQ)
Tessera Defense & Homeland Security, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. Its product pipelines include BX004 and BX005, which are treatments for cystic fibrosis and atopic dermatitis respectively. The company was founded in March 2015 and is headquartered in Dover, DE.
Sector: Services-Prepackaged Software
Industry: Biotechnology
Tessera Defense and Homeland Security Inc
OTC:HLSQHealthcare · Biotechnology
AHAfter hours+0.00%$0.0244
Prev close$0.0224+8.93%Close$0.02440.00%Now$0.0244
Close$0.0244+8.93%
Mkt Cap$634K
EV-$1.58M
Float10.01M
O/S26M
VOL297K sh
$ Vol$7K
RVOL0.22×
Inst Own0.6%
SI0.9%
Net Cash/Sh+$0.11
Dilution
MCap$634KFloat10.01MO/S26M
Dilution
Financials Summary
Revenue$0
Net Income-$36.2M
Total Assets$5.78M
Free Cash Flow-$26.39M
Debt & Equity
Debt 8%
Preferred 99%
Total Debt$1.44M
Total Equity-$1.3M
Preferred Stock$18.62M
Shares Outstanding
Short Interest
No short interest data available.
Split History3 splits · 3 reverse
2-year cumulative
1:190
Nasdaq bars a compliance period at 1:250
- 1:10Reverse splitSep 9, 202610 shares → 1
- 1:19Reverse splitNov 25, 202519 shares → 1
- 1:10Reverse splitAug 26, 202410 shares → 1
Balance Sheet Details
Assets$5.78M
Liabilities$7.08M
Accounts Receivable$0
Accounts Payable$3.12M
Inventory$0
PP&E (Net)$0
Goodwill$0
Intangible Assets$208K
Income Statement
| Period | FY 2025 |
|---|---|
| Currency | USD |
| Period Ending | 2025-12-31 |
| Revenue | $0 |
| YoY Growth | - |
| Cost of Revenue | $0 |
| Gross Profit | $0 |
| Gross Margin | - |
| Research and Development | $21.29M |
| Selling, General, and Administrative | $8.97M |
| Other | $11.2M |
| Total Operating Expenses | $41.47M |
| Operating Income (EBIT) | -$41.47M |
| Operating Margin | - |
| Interest Expense | $20K |
| Interest Income | $460K |
| Other Income (Expense) | $5.27M |
| Income Before Tax (EBT) | -$36.19M |
| Income Tax Expense | $7K |
| Net Income | -$36.2M |
| Net Income Margin | - |
| Supplementary Data | |
| EPS | -221.90 |
| Diluted EPS | -221.90 |
| Weighted Average OS | 163,103 |
| EBITDA | -$33.25M |
| EBITDA Margin | - |
Balance Sheet
| Period | FY 2025 |
|---|---|
| Currency | USD |
| Period Ending | 2025-12-31 |
| Assets | |
| Current Assets | |
| Cash and Cash Equivalents | $4.36M |
| Short-Term Investments | $0 |
| Cash and Short-Term Investments | $4.36M |
| Accounts Receivable | $0 |
| Inventory | $0 |
| Other Current Assets | $874K |
| Total Current Assets | $5.58M |
| Long-Term Assets | |
| Property, Plant & Equipment Net | $0 |
| Goodwill | $0 |
| Intangible Assets | $208K |
| Long-Term Investments | $0 |
| Deferred Tax Assets | $0 |
| Other Long-Term Assets | $0 |
| Total Long-Term Assets | $208K |
| Other Assets | $0 |
| Total Assets | $5.78M |
| Liabilities | |
| Current Liabilities | |
| Accounts Payable | $3.12M |
| Short-Term Debt | $0 |
| Current Income Tax Payable | $0 |
| Current Unearned Revenue | $0 |
| Other Current Liabilities | $0 |
| Total Current Liabilities | $6.38M |
| Long-Term Liabilities | |
| Long-Term Debt | $0 |
| Long-Term Unearned Revenue | $0 |
| Long-Term Deferred Tax Liabilities | $0 |
| Other Long-Term Liabilities | $706K |
| Total Long-Term Liabilities | $706K |
| Other Liabilities | $0 |
| Total Liabilities | $7.08M |
| Stockholders' Equity | |
| Preferred Stock | $18.62M |
| Common Stock | $7K |
| Retained Earnings | -$216.9M |
| Comprehensive Income & Other | $0 |
| Other Stockholders' Equity | $215.59M |
| Total Equity | -$1.3M |
| Minority Interest | $0 |
| Total Liabilities and Equity | $5.78M |
| Supplementary Data | |
| Total Debt | $1.44M |
| Net Debt | -$2.92M |
Cash Flow Statement
| Period | FY 2025 |
|---|---|
| Currency | USD |
| Period Ending | 2025-12-31 |
| Operating Activities | |
| Net Income | -$36.2M |
| Depreciation & Amortization | $2.92M |
| Deferred Income Tax | $0 |
| Stock-Based Compensation | $2.09M |
| Changes in Working Capital: | |
| Accounts Receivable | $0 |
| Inventory | $0 |
| Accounts Payable | $1.24M |
| Other Working Capital | -$1.26M |
| Total Working Capital Change | -$23K |
| Other Non-Cash Items | $4.82M |
| Net Cash from Operating | -$26.39M |
| Investing Activities | |
| Capital Expenditures | -$2K |
| Acquisitions | $0 |
| Purchases of Investments | $0 |
| Sales of Investments | $0 |
| Other Investing Activities | $110K |
| Net Cash from Investing | $108K |
| Financing Activities | |
| Debt Repaid | - |
| Common Stock Issuance | $13.31M |
| Common Stock Repurchases | $0 |
| Dividends Paid | $0 |
| Other Financing Activities | -$118K |
| Net Cash from Financing | $13.19M |
| Forex Effect | $73K |
| Net Change in Cash | -$13.02M |
| Supplementary Data | |
| Operating Cash Flow | -$26.39M |
| Capital Expenditure | -$2K |
| Free Cash Flow | -$26.39M |
| Cash at Beginning | $17.98M |
| Cash at End | $4.96M |